MRG-001 given at the mid-dose dramatically increased circulating CD4+Foxp3+ and CD8+Foxp3+ Tregs suggesting its immunomodulatory properties and that MRG-001 could be used as an immunoregulatory therapy in a variety of human diseases including autoimmune diseases and transplant rejection. The gene discussed is CD8A; the disease is autoimmune disease.